NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
IranMilitaryIranianStrikesOperationsGulfRegionalCrisisIsraeliNuclearPowerTargetingTimelineMarketsSupremeMarchEscalationGovernmentConflictProtestsPricesStatesDigestSuccession
IranMilitaryIranianStrikesOperationsGulfRegionalCrisisIsraeliNuclearPowerTargetingTimelineMarketsSupremeMarchEscalationGovernmentConflictProtestsPricesStatesDigestSuccession
All Articles
STAT+: A Merck cancer drug to watch
STAT News
Clustered Story
Published about 4 hours ago

STAT+: A Merck cancer drug to watch

STAT News · Mar 2, 2026 · Collected from RSS

Summary

UniQure seeks approval, Novartis settles Henrietta Lacks lawsuit, and more biotech stories

Full Article

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! The impact of President Trump’s “most-favored nation” drug-pricing push can be hard to decipher, but the policy is starting to look less like a slogan and more like a real pressure point that could mean higher prices abroad. Meanwhile, 93-year-old vaccine legend Stanley Plotkin is watching vaccination rates slip and calling the anti-vaccine turn inside government what he thinks it is: “stupid” and “immoral.” Also, a pointed warning about at-home ketamine oversight and Novartis reaches a quiet settlement in the Henrietta Lacks case. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe

Share this story
Read Original at STAT News

Related Articles

Bloomberg3 days ago
Novo Nordisk’s Torrid Week Erases Last of Wegovy-Fueled Gains

The weight loss-fueled gains of Danish drugmaker Novo Nordisk A/S are officially a thing of the past.

pmlive.com4 days ago
Novo Nordisk and Vivtex partner in deal worth up to $2 . 1bn

Published: 20260226T123000Z

STAT News5 days ago
STAT+: Novo doubles down on oral peptides

Novo slashes list prices, GSK acquires a pulmonary hypertension drug, and other biotech news

STAT News5 days ago
STAT+: Novo Nordisk strikes deal with U.S. startup to develop oral obesity, diabetes drugs

Novo Nordisk announced it had signed a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral obesity and diabetes drugs.

Bloomberg7 days ago
Novo Next-Generation Obesity Shot Falls Short of Lilly Rival

Novo Nordisk’s next-generation obesity shot delivered less weight loss than Eli Lilly rival blockbuster in yet another blow to the Danish company’s attempts to regain lost ground in the weight-loss market. People treated with a standard dose of Novo’s CagriSema in a trial achieved 20.2% weight loss after 84 weeks, compared with 23.6% for Lilly’s tirzepatide. Sam Fazeli of Bloomberg Intelligence joins to discuss. He also breaks down how Merck is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer drug Keytruda. (Source: Bloomberg)

Bloomberg7 days ago
Novo Nordisk CSO on New Obesity Shot Results and Drug Pipeline

Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)